AbbVie Submits Marketing Authorisation Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

Maidenhead, UK, 2^nd May 2018– AbbVie UK Ltd., a research-based global biopharmaceutical company, announced that it has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for risankizumab, an investigational interleukin-23 (IL-23) inhibitor, being evaluated for the treatment of patients with moderate to severe plaque psoriasis.

"The risankizumab submission to the EMA marks another significant milestone in helping to advance treatment for people living with immune-mediated diseases," said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. "Many psoriasis patients are still battling this disease and the impact it has on their lives. Risankizumab has the potential to be an important new treatment option and we look forward to working with the EMA throughout the review process."

The marketing authorisation application is supported by data from the global risankizumab Phase 3 psoriasis programme evaluating patients with moderate to severe plaque psoriasis across four pivotal Phase 3 studies: ultIMMA-1, ultIMMa-2, IMMhance and IMMvent.^1-3 Risankizumab is not approved by regulatory authorities and its safety and efficacy have not been established.

Risankizumab is part of a collaboration with Boehringer Ingelheim, with AbbVie leading future development and commercialisation of risankizumab globally.

About Risankizumab

Risankizumab is an investigational compound that is designed to selectively block IL-23 by binding to its p19 subunit.⁴ IL-23, a key cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.⁵

Risankizumab is not approved by regulatory authorities. Safety and efficacy have not been established.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2017 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

__________________________

¹ Gordon K, et al. Efficacy and Safety of Risankizumab: Results from Two Double-Blind, Placebo- and Ustekinumab-Controlled, Phase 3 Trials in Moderate-to-Severe Plaque Psoriasis. American Academy of Dermatology. February 2018.
² BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis. Clinicaltrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT02694523
³ BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment. Clinicaltrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT02672852?term=NCT02672852&rank=1
⁴ Papp K.A., et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. NEJM. 2017.
⁵ Duvallet E, Sererano L, Assier E, et. al. Interleukin-23: a key cytokine in inflammatory diseases. Ann Med. 2011 Nov;43(7):503-11.

Job code: AXHUD180551

Date of preparation: May 2018